Literature DB >> 9265622

Kinetic mechanism for p38 MAP kinase.

P V LoGrasso1, B Frantz, A M Rolando, S J O'Keefe, J D Hermes, E A O'Neill.   

Abstract

p38 has been shown to be a critical enzyme in the pro-inflammatory cytokine pathway and is a member of the mitogen-activated protein (MAP) kinase family. While the details for p38 activation and subsequent signal transduction have begun to be elucidated, little is known about the kinetic mechanism for p38. In this study, we have determined the kinetic mechanism for p38 MAP kinase. Data from initial velocity patterns in the presence and absence of a dead-end inhibitor and two triarylimidazole p38 inhibitors were consistent with an ordered sequential mechanism for p38 with protein substrate, glutathione S-transferase-activating transcription factor 2 (GST-ATF2), binding before ATP. The ATP analog, adenylyl methylenediphosphonate (AMP-PCP), and two triarylimidazoles were competitive inhibitors versus ATP and uncompetitive inhibitors versus GST-ATF2. Equilibrium binding studies utilizing a tritiated ATP-competitive inhibitor were also consistent with this mechanism and suggest an inability of ATP to bind to p38 in the absence of protein substrate. Moreover, the Michaelis constant for GST-ATF2 was 12-fold greater than the dissociation constant, indicating that the binding of ATP affected the binding of GST-ATF2. An ordered sequential mechanism with protein substrate binding first is unique to p38 compared to cyclic AMP-dependent protein kinase (cAPK) and most tyrosine kinases and helps to explain the interaction between enzyme, substrates, and inhibitors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9265622     DOI: 10.1021/bi9706778

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

1.  Biochemical characterization of cholesteryl ester transfer protein inhibitors.

Authors:  Mollie Ranalletta; Kathleen K Bierilo; Ying Chen; Denise Milot; Qing Chen; Elaine Tung; Caroline Houde; Nadine H Elowe; Margarita Garcia-Calvo; Gene Porter; Suzanne Eveland; Betsy Frantz-Wattley; Mike Kavana; George Addona; Peter Sinclair; Carl Sparrow; Edward A O'Neill; Ken S Koblan; Ayesha Sitlani; Brian Hubbard; Timothy S Fisher
Journal:  J Lipid Res       Date:  2010-05-10       Impact factor: 5.922

Review 2.  Catalytic mechanisms and regulation of protein kinases.

Authors:  Zhihong Wang; Philip A Cole
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

3.  Discovery and Characterization of a Biologically Active Non-ATP-Competitive p38 MAP Kinase Inhibitor.

Authors:  Brice A P Wilson; Muhammad S Alam; Tad Guszczynski; Michal Jakob; Shilpa R Shenoy; Carter A Mitchell; Ekaterina I Goncharova; Jason R Evans; Peter Wipf; Gang Liu; Jonathan D Ashwell; Barry R O'Keefe
Journal:  J Biomol Screen       Date:  2015-11-04

4.  Inhibition of RIP2/RIck/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK.

Authors:  Gretchen M Argast; Nelson Fausto; Jean S Campbell
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

Review 5.  Mechanistic enzymology in drug discovery: a fresh perspective.

Authors:  Geoffrey A Holdgate; Thomas D Meek; Rachel L Grimley
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

6.  Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.

Authors:  Min Liu; Brittany Dobson; Marcie A Glicksman; Zhenyu Yue; Ross L Stein
Journal:  Biochemistry       Date:  2010-03-09       Impact factor: 3.162

7.  Transcription of the transforming growth factor beta activating integrin beta8 subunit is regulated by SP3, AP-1, and the p38 pathway.

Authors:  Jennifer A Markovics; Jun Araya; Stephanie Cambier; David Jablons; Arthur Hill; Paul J Wolters; Stephen L Nishimura
Journal:  J Biol Chem       Date:  2010-06-02       Impact factor: 5.157

8.  Expression and purification of recombinant tristetraprolin that can bind to tumor necrosis factor-alpha mRNA and serve as a substrate for mitogen-activated protein kinases.

Authors:  Heping Cao; Frederick Dzineku; Perry J Blackshear
Journal:  Arch Biochem Biophys       Date:  2003-04-01       Impact factor: 4.013

9.  Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38.

Authors:  Ted Kamenecka; Jeff Habel; Derek Duckett; Weimin Chen; Yuan Yuan Ling; Bozena Frackowiak; Rong Jiang; Youseung Shin; Xinyi Song; Philip LoGrasso
Journal:  J Biol Chem       Date:  2009-03-04       Impact factor: 5.157

10.  Functions of bifans in context of multiple regulatory motifs in signaling networks.

Authors:  Azi Lipshtat; Sudarshan P Purushothaman; Ravi Iyengar; Avi Ma'ayan
Journal:  Biophys J       Date:  2008-01-04       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.